Results from ovarian cancer TCGA dataset were further corroborated by immunohistochemical analysis of CC2D1A protein expression in tumor TMAs, which showed significantly higher 5-year survival rate in patients with low CC2D1A expression than in patients with high CC2D1A expression in tumor samples (Figure 2). The gene discussed is CC2D1A; the disease is neoplasm.